From Nasdaq, Inc.:

Despite a lukewarm earnings season for the drug and biotech sector, majority of large companies reported mixed results and issued optimistic guidance for 2024. However, smaller biotechs are still scheduled to report earnings. As per the Zacks classification, 80.0% of the Medical sector companies reported earnings, with revenues rising 7.8%.

Five biotech companies are expected to deliver beats in their upcoming quarterly results – Moderna, BioMarin Pharmaceuticals, Amarin Corporation, Intellia Therapeutics, and Beam Therapeutics. These companies have high chances of delivering earnings surprises based on the Earnings ESP and positive Zacks Rank criteria.

Moderna, with an Earnings ESP of +37.55%, BioMarin with an ESP of +30.45% and Amarin with an ESP of +42.86%, are expecting their earnings results on Feb 22. Intellia Therapeutics and Beam Therapeutics are also expected to release their results soon and have a strong chance of delivering earnings surprises.

Stay on top of upcoming earnings with the Zacks Earnings Calendar and use the Earnings ESP Filter to uncover the best stocks to buy or sell before they’re reported. This can give you a significant advantage in the stock market.



Read more: 5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates